Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018225715) METHOD FOR DETERMINING RESPONSIVENESS OF MULTIPLE MYELOMA PATIENT TO DRUG, AND DRUG FOR PREVENTING AND/OR TREATING BONE LESION IN MULTIPLE MYELOMA PATIENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/225715 International Application No.: PCT/JP2018/021522
Publication Date: 13.12.2018 International Filing Date: 05.06.2018
IPC:
A61K 45/00 (2006.01) ,A61K 31/454 (2006.01) ,A61K 31/7088 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/02 (2006.01) ,C07K 16/24 (2006.01) ,C12N 15/113 (2010.01) ,C12Q 1/6851 (2018.01) ,G01N 33/68 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
445
Non-condensed piperidines, e.g. piperocaine
4523
containing further heterocyclic ring systems
454
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7088
Compounds having three or more nucleosides or nucleotides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
[IPC code unknown for C12Q 1/6851]
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
Applicants:
国立大学法人北海道大学 NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY [JP/JP]; 北海道札幌市北区北8条西5丁目 Kita 8-jyo Nishi 5-chome, Kita-ku, Sapporo-shi, Hokkaido 0600808, JP
Inventors:
清野 研一郎 SEINO Ken-ichiro; JP
バグダーディー ムハンマド BAGHDADI Muhammad; JP
Agent:
特許業務法人IPアシスト特許事務所 IP-ASSIST PATENT OFFICE; 北海道札幌市中央区北2条西3丁目1番地 太陽生命札幌ビル7階 7th-Floor, Taiyo Seimei Sapporo Building, 1, Kita 2-jyo Nishi 3-chome, Chuo-ku, Sapporo-shi, Hokkaido 0600002, JP
Priority Data:
2017-11121705.06.2017JP
Title (EN) METHOD FOR DETERMINING RESPONSIVENESS OF MULTIPLE MYELOMA PATIENT TO DRUG, AND DRUG FOR PREVENTING AND/OR TREATING BONE LESION IN MULTIPLE MYELOMA PATIENT
(FR) MÉTHODE POUR DÉTERMINER LA RÉPONSE D'UN PATIENT ATTEINT DE MYÉLOME MULTIPLE À UN MÉDICAMENT, ET MÉDICAMENT POUR PRÉVENIR ET/OU TRAITER LES LÉSIONS OSSEUSES CHEZ LES PATIENTS ATTEINTS DE MYÉLOME MULTIPLE
(JA) 多発性骨髄腫患者の医薬への応答性を判定する方法、並びに多発性骨髄腫患者における骨病変の予防及び/又は治療のための医薬
Abstract:
(EN) [Problem] To provide: a method for determining the presence or absence of responsiveness of a multiple myeloma patient to a drug, said drug comprising as an active ingredient a substance inhibiting the function of interleukin-34 (IL-34); and a drug for preventing and/or treating a bone lesion in a multiple myeloma patient. [Solution] A method for determining responsiveness of a multiple myeloma patient to a drug for preventing and/or treating a bone lesion in the subject patient, said drug comprising as an active ingredient a substance inhibiting the function of IL-34, which comprises a step for, when myeloma cells isolated from the patient are positive for IL-34 expression but negative for M-CSF expression, then determining that there is the responsiveness to the drug. The present invention makes it possible to provide to a patient a drug having an action mechanism based on the inhibition of IL-34 function, said function seeming the major causative factor for a bone lesion, while avoiding a therapeutic method having an action mechanism based on the inhibition of RANKL or M-CSF which is likely to be associated with a high risk of side effects.
(FR) Le problème que cherche à résoudre l'invention est de fournir : une méthode qui permette de déterminer la présence ou l'absence de réponse d'un patient atteint de myélome multiple à un médicament, ledit médicament comprenant comme principe actif une substance inhibant la fonction de l'interleukine-34 (IL-34) ; et un médicament pour prévenir et/ou traiter les lésions osseuses chez les patients atteints de myélome multiple. La solution apportée par l'invention concerne une méthode permettant de déterminer la réponse d'un patient atteint de myélome multiple à un médicament visant à prévenir et/ou traiter les lésions osseuses chez ce patient, ledit médicament comprenant comme principe actif une substance inhibant la fonction de l'IL-34, qui comprend une étape permettant, lorsque les cellules de myélome isolées du patient sont positives pour l'expression de l'IL-34 mais négatives pour l'expression du M-CSF, d'alors déterminer qu'il y a réponse au médicament. La présente invention permet de fournir au patient un médicament dont le mécanisme d'action est basé sur l'inhibition de la fonction de l'IL-34, ladite fonction semblant être le principal facteur induisant la lésion osseuse, tout en évitant une méthode thérapeutique dont le mécanisme d'action est basé sur l'inhibition du RANKL ou du M-CSF, qui est susceptible d'être associée à un risque élevé d'effets indésirables.
(JA) 【課題】 本発明は、多発性骨髄腫患者が、インターロイキン-34(IL-34)の機能を阻害する物質を有効成分として含有する医薬への応答性があるかを判定する方法、及び多発性骨髄腫患者における骨病変の予防及び/又は治療のための医薬を提供することを目的とする。 【解決手段】 本発明は、IL-34の機能を阻害する物質を有効成分として含有する多発性骨髄腫患者の骨病変の予防及び/又は治療のための医薬への当該患者の応答性を判定する方法であって、前記患者から単離された骨髄腫細胞がIL-34発現陽性及びM-CSF発現陰性である場合に前記医薬への応答性があると判定する工程を含む、前記判定方法に関する。本発明によれば、副作用を伴いやすいRANKL又はM-CSFの機能阻害を機序とする治療法を回避して、骨病変の主因と考えられるIL-34の機能を阻害することを機序とする医薬を患者に提供することが可能となる。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)